Menu

Blog

Jan 29, 2021

FDA delays approval decision for Biogen’s Alzheimer’s treatment

Posted by in categories: biotech/medical, neuroscience

The FDA had promised to render a decision on the approval of aducanumab by March 7. The process is now being extended to June 7.

Comments are closed.